Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse and / or Refractory Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT04756726
What this trial is testing

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Who this might be right for
Multiple MyelomaLymphoma, Non-Hodgkin's
C4 Therapeutics, Inc. 224
Not applicableWithdrawnNCT03492268
What this trial is testing

Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma

Who this might be right for
Multiple Myeloma
Bioray Laboratories
Testing effectiveness (Phase 2)Ended earlyNCT00567229
What this trial is testing

Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Memorial Sloan Kettering Cancer Center 3
Early research (Phase 1)Study completedNCT01432353
What this trial is testing

DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Genentech, Inc. 39
Very early researchUnknownNCT04412889
What this trial is testing

BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM

Who this might be right for
Multiple Myeloma
Hebei Yanda Ludaopei Hospital 18
Testing effectiveness (Phase 2)Looking for participantsNCT06232096
What this trial is testing

MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Beijing Mabworks Biotech Co., Ltd. 154
Testing effectiveness (Phase 2)Study completedNCT00558675
What this trial is testing

A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy

Who this might be right for
Hematological MalignancyLeukemiaLymphoma+1 more
Mirror Biologics, Inc. 6
Testing effectiveness (Phase 2)Study completedNCT01955434
What this trial is testing

SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Mayo Clinic 25
Testing effectiveness (Phase 2)WithdrawnNCT00085345
What this trial is testing

Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Stage II Multiple MyelomaStage III Multiple MyelomaRefractory Plasma Cell Neoplasm
Oncotherapeutics
Not applicableStudy completedNCT00005799
What this trial is testing

Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+42 more
Fred Hutchinson Cancer Center 55
Very early researchUnknownNCT04182581
What this trial is testing

BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Xijing Hospital 18
Early research (Phase 1)Study completedNCT03338972
What this trial is testing

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Fred Hutchinson Cancer Center 28
Early research (Phase 1)Looking for participantsNCT07255898
What this trial is testing

BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

Who this might be right for
Multiple MyelomaHematologic Malignancies
Sichuan Baili Pharmaceutical Co., Ltd. 33
Early research (Phase 1)Looking for participantsNCT05650632
What this trial is testing

Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
AbbVie 210
Testing effectiveness (Phase 2)WithdrawnNCT03701321
What this trial is testing

Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Looking for participantsNCT06292780
What this trial is testing

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

Who this might be right for
Relapsed/Refractory Systemic Light Chain Amyloidosis
Regeneron Pharmaceuticals 220
Testing effectiveness (Phase 2)Ended earlyNCT00352742
What this trial is testing

ATN-224 and Bortezomib in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Attenuon 46
Testing effectiveness (Phase 2)UnknownNCT03312205
What this trial is testing

CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Who this might be right for
LeukemiaLymphomaMultiple Myeloma of Bone (Diagnosis)
Hebei Senlang Biotechnology Inc., Ltd. 50
Testing effectiveness (Phase 2)Study completedNCT00814541
What this trial is testing

PAD. ICORG 05-01, V11

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Cancer Trials Ireland 53
Large-scale testing (Phase 3)Study completedNCT03859427
What this trial is testing

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Amgen 454
Next Page